NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.
Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians
An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).
NovaVive Presents Data Demonstrating Reduction in Antibiotic Use with MCWF in Young Calves
NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.
Equine Sarcoid Tumor Product Now Available to U.S. Veterinarians
NovaVive now offers an equine-specific version of its Immunocidin® product for equine sarcoids in response to demand by U.S. veterinarians. Immunocidin® Equine is packaged in 5mL vials for the convenience of practitioners.
Antibiotic Alternative for Cattle Now Available to Canadian Veterinarians
Amplimune™ is now available to Canadian veterinarians. Amplimune is an immunomodulator that reduces the clinical signs/mortality associated with E. coli diarrhea in neonatal calves. It offers an alternative to antibiotics.
Antibiotic Alternative for Cattle Approved for Sale in Canada by the Canadian Food Inspection Agency
Amplimune™ has received approval for sale in Canada by the Canadian Food Inspection Agency. The Company believes this is the first antibiotic alternative therapy for livestock to receive Canadian regulatory approval.